



# Enhancing the Collection, Analysis and Availability of Demographic Subgroup Data

Public Meeting: February 29, 2016

---

- 9:00 – 9:10 am      **Welcome**  
Barbara Buch, MD, Center for Biologics Evaluation and Research (CBER),  
FDA Safety and Innovation Act (FDASIA) Section 907 Steering Committee  
Chair
- 9:10 – 9:20 am      **Opening Remarks** “*The Shifting Paradigm and FDA’s Current Thinking*”  
Robert Califf, MD, MACC, Commissioner of Food and Drugs
- 9:20 – 10:30 am      **Progress in Data Quality, Participation, and Transparency at FDA**  
Moderator: Barbara Buch, MD, CBER  
*Center for Biologics Evaluation and Research (CBER)*  
Barbara Buch, MD, CBER  
*Center for Devices and Radiological Health (CDRH)*  
Kathryn (Katie) O’Callaghan, Acting Senior Advisor, Strategic  
Partnerships, CDRH  
*Center for Drug Evaluation and Research (CDER)*  
John Whyte, MD, MPH, Director of Professional Affairs and  
Stakeholder Engagement (PASE), CDER  
*Office of Women’s Health (OWH)*  
Marsha Henderson, MCRP, Assistant Commissioner for Women’s  
Health  
*Office of Minority Health (OMH)*  
Jonca Bull, MD, Assistant Commissioner for Minority Health
- 10:30 – 10:45 am      **Kick-Off** “*Ancestry NOT Race or Ethnicity, Moving Towards Precision  
Medicine*”  
Charles Rotimi, PhD, Chief and Senior Investigator, Metabolic, Cardiovascular  
and Inflammatory Disease Genomics Branch  
Director, Center for Research on Genomics and Global Health, National Human  
Genome Research Institute, National Institutes of Health (NIH)
- 10:45-10:55 am      **Break**
- 10:55 – 12:10 pm      **Panel 1: Challenges and Solutions**  
Moderator: Kathryn (Katie) O’Callaghan, CDRH  
Panelists:  
*Government Perspectives*
  - Cara James, PhD, Director, Office of Minority Health at the Centers  
for Medicare and Medicaid Services (CMS)
  - Janine Clayton, MD, Director, Office of Research on Women's  
Health, NIH

\*Members of the public who have signed up to speak



# Enhancing the Collection, Analysis and Availability of Demographic Subgroup Data

Public Meeting: February 29, 2016

---

10:55 – 12:10 pm	<b>Continued</b> <i>Public-Private Partnership Perspective</i> <ul style="list-style-type: none"><li>▪ Jamie Roberts, MA, CCRP, MPH[c] Senior Clinical Project Manager Clinical Trials Transformation Initiative</li></ul> <i>Community Research Perspective</i> <ul style="list-style-type: none"><li>▪ Carol Horowitz, MD, MPH, Associate Professor Population Health Science and Policy, Associate Professor Medicine, General Internal Medicine, Mount Sinai</li></ul> <i>Industry Perspective</i> <ul style="list-style-type: none"><li>▪ Kara Haas, MD, MPH, FACS, RAC, Director, Global Regulatory Affairs Policy and Intelligence, Medical Devices, Johnson &amp; Johnson, AdvaMed</li></ul>
12:10 – 12:40 pm	<b>Public Session*</b>
12:40 – 1:40 pm	<b>Lunch (on your own)</b>
1:40 – 2:55 pm	<b>Panel 2: The Future</b> Moderator: John Whyte, MD, MPH, Director of PASE, CDER Panelists: <ul style="list-style-type: none"><li>▪ Allison Kalloo, Patient Perspective, Founder, #iParticipate</li><li>▪ Robert Temple, MD, Deputy Center Director for Clinical Science, CDER</li><li>▪ Lisa LaVange, PhD, Director, Office of Biostatistics, Office of Transitional Sciences, CDER</li><li>▪ Rita Redberg, MD, MSc, Professor and Director, Women’s Cardiovascular Services, University of California, San Francisco Advisor, Women’s Heart Alliance</li><li>• Jocelyn Ulrich, MPH, Assistant Vice President, Science &amp; Regulatory Advocacy, PhRMA</li></ul>
2:55 – 3:05 pm	<b>Break</b>
3:05 – 3:35 pm	<b>Public Session*</b>
3:35 – 3:45 pm	<b>Closing Remarks and Wrap Up</b> Barbara Buch, MD, FDA FDASIA Section 907 Steering Committee Chair

\*Members of the public who have signed up to speak